Baird Financial Group’s GSK GSK Stock Holding History

Baird Financial Group’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.32M	Sell	23,839 -9,696	-29%	-$525K	﹤0.01%	1176
2025 Q4	$1.64M	Buy	33,535 +14,406	+75%	+$672K	﹤0.01%	1101
2025 Q3	$826K	Sell	19,129 -2,653	-12%	-$104K	﹤0.01%	1322
2025 Q2	$836K	Sell	21,782 -3,008	-12%	-$115K	﹤0.01%	1261
2025 Q1	$960K	Buy	24,790 +1,179	+5%	+$43.2K	﹤0.01%	1193
2024 Q4	$799K	Sell	23,611 -297	-1%	-$10.7K	﹤0.01%	1241
2024 Q3	$977K	Sell	23,908 -71,209	-75%	-$2.91M	﹤0.01%	1179
2024 Q2	$3.66M	Sell	95,117 -60,828	-39%	-$2.56M	0.01%	758
2024 Q1	$6.69M	Sell	155,945 -39,480	-20%	-$1.63M	0.01%	589
2023 Q4	$7.24M	Buy	195,425 +37,961	+24%	+$1.36M	0.02%	551
2023 Q3	$5.71M	Buy	157,464 +41,044	+35%	+$1.46M	0.02%	585
2023 Q2	$4.15M	Buy	116,420 +33,296	+40%	+$1.19M	0.01%	676
2023 Q1	$2.96M	Buy	83,124 +18,946	+30%	+$663K	0.01%	764
2022 Q4	$2.25M	Buy	64,178 +25,008	+64%	+$833K	0.01%	842
2022 Q3	$1.15M	Sell	39,170 -17,584	-31%	-$666K	﹤0.01%	1003
2022 Q2	$3.09M	Buy	56,754 +6,548	+13%	+$361K	0.01%	704
2022 Q1	$2.73M	Sell	50,206 -4,648	-8%	-$252K	0.01%	788
2021 Q4	$3.02M	Sell	54,854 -3,113	-5%	-$162K	0.01%	779
2021 Q3	$2.77M	Sell	57,967 -893	-2%	-$44.9K	0.01%	807
2021 Q2	$2.93M	Sell	58,860 -2,950	-5%	-$142K	0.01%	770
2021 Q1	$2.76M	Sell	61,810 -166,814	-73%	-$7.57M	0.01%	769
2020 Q4	$10.5M	Sell	228,624 -5,397	-2%	-$248K	0.03%	375
2020 Q3	$11M	Buy	234,021 +8,891	+4%	+$445K	0.04%	349
2020 Q2	$11.5M	Sell	225,130 -5,966	-3%	-$306K	0.04%	323
2020 Q1	$10.9M	Sell	231,096 -1,578	-0.7%	-$84.2K	0.05%	304
2019 Q4	$13.7M	Buy	232,674 +1,524	+0.7%	+$84.8K	0.05%	327
2019 Q3	$12.3M	Sell	231,150 -8,352	-3%	-$430K	0.05%	322
2019 Q2	$12M	Buy	239,502 +27,332	+13%	+$1.37M	0.05%	332
2019 Q1	$11.1M	Buy	212,170 +43,716	+26%	+$2.18M	0.06%	304
2018 Q4	$8.05M	Buy	168,454 +118,015	+234%	+$5.81M	0.05%	327
2018 Q3	$2.52M	Sell	50,439 -1,031	-2%	-$52.4K	0.02%	608
2018 Q2	$2.59M	Buy	51,470 +1,852	+4%	+$93.3K	0.02%	592
2018 Q1	$2.42M	Sell	49,618 -43,655	-47%	-$2.03M	0.02%	589
2017 Q4	$4.14M	Sell	93,273 -19,277	-17%	-$891K	0.03%	457
2017 Q3	$5.71M	Sell	112,550 -4,966	-4%	-$252K	0.04%	390
2017 Q2	$6.33M	Sell	117,516 -793	-0.7%	-$42.3K	0.05%	352
2017 Q1	$6.24M	Sell	118,309 -3,305	-3%	-$168K	0.05%	346
2016 Q4	$5.85M	Sell	121,614 -40,943	-25%	-$2.02M	0.05%	342
2016 Q3	$8.76M	Sell	162,557 -1,388	-0.8%	-$76.1K	0.08%	261
2016 Q2	$8.92M	Sell	163,945 -3,793	-2%	-$200K	0.08%	252
2016 Q1	$8.5M	Sell	167,738 -37,931	-18%	-$1.89M	0.08%	250
2015 Q4	$10.4M	Sell	205,669 -17,795	-8%	-$907K	0.1%	204
2015 Q3	$10.7M	Buy	223,464 +796	+0.4%	+$41.4K	0.11%	191
2015 Q2	$11.6M	Buy	+222,668	New	+$12.5M	0.11%	201

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Baird Financial Group's GSK Position: Q1 2026 in Review

Baird Financial Group reduced its GSK (GSK) stake by 29% in Q1 2026, selling an estimated $525K and leaving 23,839 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1176.

Baird Financial Group first reported a position in GSK in Q2 2015 and has held it in 44 quarters since. The position peaked at $13.7M in Q4 2019. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Baird Financial Group held 23,839 shares of GSK worth $1.32M as of Q1 2026.
Baird Financial Group sold 9,696 GSK shares in Q1 2026, an estimated $525K.
GSK made up ﹤0.01% of Baird Financial Group's portfolio in Q1 2026, its #1176 holding.
Baird Financial Group first reported a position in GSK in Q2 2015 and has held it in 44 quarters since.
Baird Financial Group's GSK position peaked at $13.7M in Q4 2019.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Baird Financial Group's 13F filing for Q1 2026, filed 14 May 2026.